Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults

Journal of Infectious Diseases

Volumn 188, Issue 2, 2003, Pages 219-227

  Pitisuttithum, Punnee ^a,l   Nitayaphan, Sorachai ^c   Thongcharoen, Prasert ^b   Khamboonruang, Chirasak ^f   Kim, Jerome ^g,j   De Souza, Mark ^d,h   Chuenchitra, Thippawan ^b   Garner, Robin P ^g,h   Thapinta, Darawan ^f   Polonis, Victoria ^d,g,h   Ratto Kim, Silvia ^g,h   Chanbancherd, Penprapa ^e   Chiu, Joseph ^f,h,k   Birx, Deborah L ^g   Duliege, Anne Marie ⁱ   McNeil, John G ^g   Brown, Arthur E ^d  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^d US Components Armed Forces Res I   (Thailand)

^e Army Institute of Pathology   (Thailand)

^f CHIANG MAI UNIVERSITY   (Thailand)

^g WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^h HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j Hawaii AIDS Clin Research Program   (United States)

^k NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^l MAHIDOL UNIVERSITY   (Thailand)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CM235 GLYCOPROTEIN GP 120 VACCINE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; SF2 GLYCOPROTEIN GP 120 VACCINE; UNCLASSIFIED DRUG;

ADULT; ANTIGENICITY; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; INFECTION RISK; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THAILAND;

ADULT; AIDS VACCINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MALE; NEUTRALIZATION TESTS; THAILAND;

EID: 0042315405     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/376506     Document Type: Article

References (32)

1. Joint United Nations Programme on HIV/AIDS and World Health Organization. AIDS epidemic update, December 2001. Available at: http://www.unaids.org.
2. Joint United Nations Program on HIV/AIDS and World Health Organization. Epidemiological fact sheet on HIV/AIDS and sexually transmitted infections: Thailand, 2000 update. Available at: http://www.unaids.org.
3. Nelson KE, Celentano DD, Eiumtrakol S, et al. Changes in sexual behavior and a decline in HIV infection among young men in Thailand. N Engl J Med 1996; 335:297-303.
4. Girard MP, Excler JL. Human immunodeficiency virus. In: Plotkin SA, Orenstein WA, eds. Vaccines. 3rd ed. Philadelphia: WB Saunders, 1999:928-67.
5. Kalish ML, Baldwin A, Raktham S, et al. The evolving molecular epidemiology of HIV-1 envelope subtypes in injecting drug users in Bangkok, Thailand: implications for vaccine trials. AIDS 1995; 9:851-7.
6. Subbarao S, Limpakarnjanarat K, Mastro TD, et al. HIV type 1 in Thailand, 1994-1995: persistence of two subtypes with low genetic diversity. AIDS Res Hum Retroviruses 1998; 14:319-27.
7. Qu CY, Takebe Y, Luo CC, et al. Wide distribution of two subtypes of HIV-1 in Thailand. AIDS Res Hum Retroviruses 1992; 8:1471-2.
8. McCutchan FE, Hegerich PA, Brennan TP, et al. Genetic variants of HIV-1 in Thailand. AIDS Res Hum Retroviruses 1992; 8:1887-95.
9. Limpakarnjanarat K, Ungchusak K, Mastro TD, et al. The epidemiological evolution of HIV-1 subtype B and E among heterosexuals and injecting drug users in Thailand, 1992-1997. AIDS 1998; 12:1108-9.
10. Berman PW, Matthews TJ, Riddle L, et al. Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1. J Virol 1992; 66:4464-9.
11. Belshe RB, Clements ML, Dolin R, et al. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. J Infect Dis 1993; 168:1387-95.
12. Belshe RB, Graham BS, Keefer MC, et al. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA 1994; 272:475-80.
13. Gorse GJ, Corey L, Patel GB, et al. HIV-1 MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1 MN recombinant glycoprotein 120 vaccine. AIDS Res Hum Retroviruses 1999; 15:115-32.
14. Gorse GJ, McElrath MJ, Matthews TJ, et al. Modulation of immunologic responses to HIV-1 MN recombinant gp160 vaccine by dose and schedule of administration. Vaccine 1998; 16:493-506.
15. Gorse GJ, Frey SE, Patel G, Newman FK, Belshe RB. Vaccine-induced antibodies to native and recombinant human immunodeficiency virus type 1 envelope glycoproteins. Vaccine 1994; 12:912-8.
16. Graham BS, Keefer MC, McElrath MJ, et al. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120: a randomized, double-blind trial. Ann Intern Med 1996; 125:270-9.
17. Keefer MC, Graham BS, Belshe RB, et al. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. AIDS Res Hum Retroviruses 1994; 10:1713-23.
18. Keefer MC, Graham BS, McElrath MJ, et al. Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. AIDS Res Human Retroviruses 1996; 12:683-93.
19. Schwartz DH, Gorse G, Clements ML, et al. Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1 IIIB rgp120 subunit vaccine. Lancet 1993; 342:69-73.
20. Nitayaphan S, Khamboonruang C, Sirisophana N, et al. A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais. Vaccine 2000; 18:1448-55.
21. Migasena S, Suntharasamai P, Pitisuttithum P, et al. AIDSVAX (MN) in Bangkok injecting drug users: a report on safety and immunogenicity, including macrophage-tropic virus neutralization. AIDS Res Hum Retroviruses 2000; 16:655-63.
22. Mascola JR, Snyder SW, Weislow OS, et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. J Infect Dis 1996; 173:340-8.
23. Zolla-Pazner S, Alving C, Belshe R, et al. Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines. J Infect Dis 1997; 175:764-74.
24. VanCott TC, Bethke FR, Burke DS, Redfield RR, Birx DL. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J Immunol 1995; 155:4100-10.
25. Earl PL, Broder CC, Long D, et al. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol 1994; 68:3015-26.
26. Broder CC, Earl PL, Long D, Abedon ST, Moss B, Doms RW. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies. Proc Natl Acad Sci USA 1994; 91:11699-703.
27. VanCott TC, Mascola JR, Loomis-Price LD, et al. Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope. J Virol 1999; 73:4640-50.
28. Berman PW, Huang W, Riddle L, et al. Development of bivalent (B/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand. Virology 1999; 265:1-9.
29. Mascola JR. Neutralization of HIV-1 infection of human peripheral blood mononuclear cells (PBMC): antibody dilution method. In: Michael NL, Kim JH, eds. HIV protocols. Vol. 17. Totowa, NJ: Humana Press, 1999:309-15.
30. Ratto-Kim S, Sitz KV, Garner RP, et al. Repeated immunization with recombinant gp160 human immunodeficiency virus (HIV) envelope protein in early HIV-1 infection: evaluation of the T cell proliferative response. I Infect Dis 1999; 179:337-44.
31. Coraham BS, Wright PF. Candidate AIDS vaccines. N Engl J Med 1995; 333:1331-9.
32. Keefer MC, Wolff M, Gorse GJ, et al. Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses 1997; 13:1163-77.